# RNN 1st Gen Model Cardinal Health, Inc. Drugs, proprietaries, & sundries

Stock predictor AI models:
68.18% successful of 44 deals
$ 52.97 Last close price
at 02-mar-2021


Model's trade recommendations 2.64% Return for period

-10.86% Annual return

$20.35B Market Cap

β 1.06  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 2.64%
52wk return -14.81%
52wk Range
Sortino ratio -0.84
Sharpe ratio -0.82
Norm. RMSE 1.03%
Downside risk 12.90%
Volatility 0.00%
  • 1.85 (2.86%) Div (Yield)
  • HOLD Analysts consensus recommendation

Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically proven medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency from hospital to home. Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management.

Industry sector: Medical

Sector classification: Drugs, proprietaries, & sundries

Deep Learning based analysis and prediction model for Cardinal Health, Inc. (CAH) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for CAH model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for CAH.

Model is being retrained on a daily basis.

Float 312M
P/E 12.34
Shares Outstanding 315M
% Held by Insiders 0.97%
% Held by Institutions 89.95%
EPS (last reported FY) $5.40
EPS (last reported Q) $1.31
EPS, estimated (last reported Q) $1.14
Total revenues $130 B
Net income $1 B